We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 256

Federal Court Reissues its Original Decision to Award Section 8 Damages After the Federal Court of Appeal Held the Original Decision Relied on Inadmissible Hearsay Evidence
  • Borden Ladner Gervais LLP
  • Canada
  • June 7 2017

The Federal Court has reaffirmed and reissued its original decision awarding section 8 damages to Teva following a redetermination that was ordered by


Apotex's claims against current and former Ministers and civil servants working at the Ministry of Health is not struck for a lack of jurisdiction
  • Borden Ladner Gervais LLP
  • Canada
  • May 31 2017

The Federal Court has refused to strike a claim brought by Apotex against current and former ministers and civil servants working at the Ministry of


Motion to Amend Dismissed in Respect of the Contested Amendments
  • Borden Ladner Gervais LLP
  • Canada
  • June 7 2017

The Court dismissed the Plaintiffs by Counterclaim's motion to amend their statement of defence and counterclaim in respect of the contested


Appeal of a finding of non-infringement of a U.S. Patent dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • May 31 2017

The Ontario Court of Appeal dismissed an appeal of the Trial Judge's decision finding that the Respondent had not infringed the Appellant's patent in


Court grants motion to reopen trial and admit new evidence
  • Borden Ladner Gervais LLP
  • Canada
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued


Prothonotary's Dismissal of a PM(NOC) application pursuant to s. 6(5)(b) upheld on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2016

Celltrion brought a motion pursuant to s. 6(5)(b) of the Patented Medicines (Notice of Compliance) Regulation (the NOC Regulations) to have the


Findings Made in Section 8 Case to Allow Determination of Quantum of Damages
  • Borden Ladner Gervais LLP
  • Canada
  • May 10 2017

In this case, Teva is seeking compensation pursuant to s. 8 of the NOC Regulations for having been prevented from coming to market with its generic


Teva's allegation for section 8 damages not struck on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review


Appeal upholds dismissal of request to amend pleadings due to proximity to trial
  • Borden Ladner Gervais LLP
  • Canada
  • April 4 2014

This case concerns an appeal of a motion to amend pleadings in the s. 8 case described above. The motion had originally been brought three months


Motion to strike judicial review application dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • January 5 2011

Apotex brought a judicial review application in respect of decisions made by the Minister of Health (the Minister) related to the review and approval of a submission relating to Apo-Omeprazole tablets